RE:RE:RE:RE:RE:EY sees bolt-ons in the single to double digit billions now Companies like Pfizer, have already stated they they would like to partner in the IO space on pre-clinical and clinical stage immunomodulatory opportunities, with an emphasis on those agents that directly engage or impact T-cell and other tumor infiltrating lymphocyte cell populations, and are seeking Platforms Technologies, like ONCY's Immune Molecule Platform Technology (pelareorep) that is a new modality which induces immune responses, by "Priming" the immune system and converting the TME for the sequential synergistic addition of checkpoint inhibitors and CAR-T therapies to the OV pelareorep, for example.
And since ONCY is successfully collaborating with several Big Pharma companies, an acquisition of ONCY should be the next step.
https://www.pfizer.com/partners/candidate/oncology